Some scholars found in the study of prostate cancer [18] that PLAC1 has high reactivity in prostate cancer cells, and antibody-drug conjugates based on anti PLAC1 may pave the way for the development of more reliable, efficient and new immunotherapy for prostate cancer patients. The gene discussed is PLAC1; the disease is Familial prostate cancer.